Clinically, advanced NSCLC patients usually have progression of disease due to acquired drug resistance after 9 to 13 months treatment with EGFR-TKI, and it’s a concerned problem on how to treat after drug resistance[11–13], and many related clinical trials were reported[14,15]. This evidence concerns the gene EGFR and non-small cell lung carcinoma.